You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 297 No. 20, May 23/30, 2007 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (3)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Cardiovascular System
 •Cardiovascular Disease/ Myocardial Infarction
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Statins and Regression of Coronary Atherosclerosis

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Nicholls and colleagues1 found that treatment with statins was associated with regression of coronary atherosclerosis (assessed by intravascular ultrasonography) when low-density lipoprotein cholesterol (LDL-C) was substantially reduced and high-density lipoprotein cholesterol (HDL-C) was increased by more than 7.5%. The authors state that it remains to be determined whether these changes translate to improved clinical outcomes because the small increases in HDL-C observed during statin therapy have never been shown to correlate with clinical outcome.

However, in a post hoc analysis of the secondary coronary heart disease prevention Greek Atorvastatin Coronary Heart Disease Evaluation (GREACE) Study, the composite end point of all vascular events was found to be partly determined by the extent of atorvastatin-induced HDL-C increase in the structured care group compared with usual care.2 This was in the setting of achieving an LDL-C level of 100 mg/dL (2.59 mmol/L) in 95% of patients in the . . . [Full Text of this Article]

Vasilios G. Athyros, MD
athyros@med.auth.gr

Anna Kakafika, MD; Asterios Karagiannis, MD
Aristotelian University
Thessaloniki, Greece

Dimitri P. Mikhailidis, MD, FFPM, FRCP, FRCPath
Royal Free University College Medical School
London, England



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTER

Statins and Regression of Coronary Atherosclerosis--Reply
, , and
JAMA. ;297():2197-2197.
FULL TEXT  

RELATED ARTICLE

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
, , , , , , , , , , , and
JAMA. ;297():499-508.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure?
Pagourelias et al.
ANGIOLOGY 2009;60:74-81.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.